Novartis To Discontinue Hepatitis And Invasive Candidiasis Drug Developments

Links shared publicly online about this topic.

820
total visits

Novartis To Discontinue Hepatitis And Invasive Candidiasis Drug Developments

Novartis says it is to discontinue further development of two investigational compounds (drugs), Albinterferon alfa-2b for adults with chronic hepatitis C and Mycograb (efungumab) an antifungal a

View full resource at medicalnewstoday.com

Tags: Liver Condition, Hepatitis, Yeast Infection, Candidiasis, Vaginal Infection, Drug, Novartis

Most Recently Shared on October 7, 2010 at 3:05 am By:

MNT Infect Diseases

Novartis To Discontinue Hepatitis And Invasive Candidiasis Drug Developments http://mnt.to/3KSt #viruses #bacteria

2 years ago...

Retweet

Favorite

Also Shared By:

OrganizedWisdom

Novartis To Discontinue Hepatitis And Invasive Candidiasis Drug Developments

Novartis To Discontinue Hepatitis And Invasive Candidiasis Drug Developments

Most Recently Shared on October 7, 2010 at 3:05 am By:

Also Shared By:

Verify on Twitter to Claim Your Profile

Make an Appointment

Consulting Inquiry

Verify Information